1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026

Report Details
AMD and Other Retinal Diseases – our new study reveals trends, R&D progress, and predicted revenues
Where is the AMD and Other Retinal Diseases market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2026, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 169 page report provides 50 tables and 42 figures. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing AMD and Other Retinal Diseases market. See how to exploit the opportunities.

Forecasts from 2016-2026 and other analyses reveal the commercial prospects
- In addition to revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares.
- You find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments.
- Read full transcripts of two exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:
- Dr. Leigh J. Hsu, Vice President, Corporate Development & Strategy, Lpath, Inc.
- Philip G. Ralston, Jr., MacuCLEAR.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you find revenue forecasts to 2026 for the following submarkets:
- Wet age-related macular degeneration (wAMD)
- Dry AMD (dAMD)
- Diabetic retinopathy (DR)
- Other retinal diseases (grouped forecast).

Our investigation discusses what stimulates and restrains business. Understand the dynamics of the industry and assess its potential future sales, discovering the critical factors likely to achieve success.

Predictions of leading products’ sales – what’s possible for those eye drug revenues?
How will individual retinal medicines perform from 2016 to 2026 at world level? Our study forecasts revenues of five prominent brands:
- Lucentis
- Eylea
- Avastin
- Visudyne
- Jetrea.

Discover how high revenues can go. See what's happening, understanding the trends, challenges and opportunities.

Our analysis also divides the main global forecast into geographical markets.

What are the prospects in the leading regions and countries?
You will discover individual revenue forecasts for 10 leading national markets from 2016-2026:
- United States (US)
- Japan
- Germany, France, the UK, Italy and Spain (EU5 group)
- Brazil, Russia, India and China (BRIC countries).

There you will find countries with the highest revenues and potential growth. You can explore the outlook for treating ocular problems, serving doctors’ and patients’ needs. Assess the opportunity and ways to help people retain eyesight. Discover what the commercial prospects are for you and your organisation.

Leading companies and the potential for market growth
Our analyses forecasts the world market for retinal drugs will reach $17.38bn in 2020. It will achieve strong revenue expansion from 2016 to 2026. Our report reveals how high sales will go.

You can also see which companies hold the most potential. Examine eye drug developers, producers and marketers, including these firms:
- Novartis
- Roche
- Regeneron
- Bayer
- Santen
- Valeant
- Allergan

Research and development - assess innovation, trends and possibilities
There you can also investigate R&D, appraising technological, clinical and commercial possibilities.
In our study explore the research and development in slowing vision loss and restoring sight. You can examine these advances and others:
- Combination therapies, including neovascularisation disrupters
- Angiogenesis inhibition by blocking pericyte recruitment
- Anti-inflammatory mechanisms (inc. corticosteroids)
- Targeting VEGF and PDGF (inc. receptors, kinases and angiogenesis pathways)
- Monoclonal antibodies, mAb fragments, DARPins (designed ankyrin repeat proteins) and visual cycle modulators.

Explore the other agents and possibilities, too, including these:
- Oligonucleotides and siRNA therapy
- Anti-integrin oligopeptide treatment
- Complement factor inhibition and serotonin modifiers
- Angiotensin receptor blockers and converting enzyme inhibitors
- Biosimilars and other follow-on biologicals and next generation therapeutics
- Regenerative medicine, neural stem cells (NSCs), cellular and gene therapies.

The R&D holds strength, variety and promise. See what’s possible for big pharma companies and specialists in biological drugs (biologics) and other biotechnologies.

How the AMD and Other Retinal Diseases report helps you
- Revenues for retinal disease treatments to 2026 – assess the overall world drugs market’s potential and receive forecasted revenues for treating wet age-related macular degeneration (wAMD), dry AMD, diabetic retinopathy (DR) and other disorders
- Products’ sales to 2026 – discover the predicted revenues of Lucentis, Eylea, Avastin, Visudyne and Jetrea, seeing how those medicines can compete and succeed
- National market forecasting to 2026 for 11 countries in the Americas, Europe and Asia – explore the best regions for treatment demand, sales and growth
- R&D activities – see the progress, trends and prospects in that ophthalmic research and development, finding technological, clinical and commercial possibilities
- Companies, news and opinions – examine the participants, including Roche, Novartis, Bayer, Regeneron and Allergan, and receive two exclusive interviews, helping your reputation for insight and staying ahead
- Analysis of what stimulates and restrains that industry and market – assess challenges and strengths there, helping you compete and gain advantage.

Our brand new survey, by our in-house UK-based analysts, provides knowledge to benefit your research, analyses, plans, decisions and proposals. It reveals information you will find nowhere else.

Discover predictions for rear-eye medicines, getting information to help you now
With our independent analyses explore products, companies, progress and possibilities. Discover the best commercial opportunities, as well as ways to help patients.

Having that market data means you’re less likely to fall behind in knowledge or miss a crucial opportunity. Through your choice find how you could save time and effort, also benefiting your authority, reputation and results.

Our investigation provides you with definitive data, trends, opportunities and sales predictions to 2025 for retinal pharmaceuticals. So avoid missing out – please order the report now.

Table Of Contents

Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026
1. Report Overview
1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. World AMD and Other Disease Market, 2015
2.1 What are Retinal Diseases?
2.2 Types of Retinal Diseases
2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
2.4 Nearly 200 Million People with AMD?
2.5 Over 100 Million with DR
2.6 First RVO Estimates Suggest Patient Population of 16 Million
2.7 Market to Make Rapid Pace to 2026
2.8 Eylea Became Leading drug in the Market
2.9 Regeneron the Leading Presence in the Market
2.10 Which are the Most Significant Disease Areas for the Market?

3. Retinal Disease Market Subsectors, 2015
3.1 Wet AMD Still the Main Source of Revenue in the Market
3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
3.2.1 Revenue Forecasting for Wet AMD segment, 2015-2026
3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
3.3.1 Dry AMD Segment to Emerge in the Forecast Period
3.4 DR: Coming Into Clinical Focus, with DME the Main Target
3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues
3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
3.6 Projections for All Segments, 2015-2026

4. Approved Products in the AMD and Other Retinal Diseases Market, 2015-2026
4.1 Will the Current Products Dominate the Market Through 2026?
4.2 Lucentis: Second Leading Drug in the Market
4.2.1 Positive Revenue Growth Shown in Past: 2012-2015
4.2.2 Shadow of Avastin Still Hangs Over Lucentis
4.2.3 CATT Study Results: Clinical Differences Still Have Yet to Emerge
4.2.4 Eylea: The Bigger Threat to Lucentis? (might shift in eylea section)
4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
4.2.6 Improving Cost and Compliance for Lucentis
4.2.7 Lucentis Revenue Forecast 2015-2026
4.2.8 Will Loss of Physician Goodwill Harm Lucentis' Growth?
4.3 Eylea: Holds the Throne?
4.3.1 Increasing Revenue Growth in Past: Outside US Sale Amplified
4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
4.3.3 First Wave of Eylea's Expansion Finally Beginning to Break?
4.3.4 Eylea into DME and Other New Indications
4.3.5 Eylea Revenue Forecast 2015-2026
4.3.6 How Far Can Eylea's Momentum Carry It?
4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
4.4.2 Judicial Review Averted in the UK by Price Adjustment
4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007
4.4.4 Roche and Novartis Challenge CATT's Headline Conclusions
4.4.5 Will Eylea/Zaltrap Affect Avastin's Place in the Market?
4.4.6 Avastin Revenue Forecast, 2015-2026
4.4.7 Will Anything Dislodge Avastin from its Central Position?
4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
4.5.1 Visudyne Revenue Forecast, 2015-2026
4.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
4.6.1 Jetrea Revenue Forecast, 2015-2026

5. Pipeline for Wet AMD Segment, 2015-2026
5.1 The Leading Pipeline Candidates
5.2 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
5.2.1 Three Phase 3 Trials to Confirm Fovista's Outstanding Phase 2 Results
5.2.2 Ophthotech Goes Public to Fund Phase 3 Effort
5.2.3 Ophthotech Partners with Novartis for Fovista
5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
5.2.5 The Move toward Combination Therapies
5.3 Other Growth Factor Targets in the Pipeline
5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
5.3.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
5.3.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
5.4 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
5.4.1 A Chinese Competitor: Where Will Conbercept Fit In?
5.4.2 Binding Affinity Comparable to Eylea
5.5 Do We Need New Anti-VEGFR Agents or Delivery Systems?
5.5.1 Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
5.5.2 Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
5.5.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
5.5.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
5.5.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
5.5.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
5.6 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
5.6.1 Verisome System and IBI-30089 (Icon Bioscience)
5.6.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
5.7 Other Targets Under Investigation in wAMD Drug Development
5.7.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
5.7.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
5.7.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
5.7.4 Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
5.7.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?
5.7.6 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
5.7.7 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
5.7.8 Novel Anti-Angiogenic Treatments in Development: Ora Bio's ORA102 and CoMentis' ATG003
5.7.9 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
5.7.10 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
5.8 Regenerative Medicine Approaches
5.8.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
5.8.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
5.8.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes

6. Pipeline for Dry AMD Segment, 2015-2026
6.1 Who Will Achieve the Big Breakthrough in Dry AMD?
6.2 MC-1101 (MacuCLEAR): Leading the Pack?
6.2.1 Increasing Choroidal Blood Flow with Repurposed Product
6.2.2 Novel Endpoints in Phase 3 Study
6.2.3 Can MacuCLEAR Make It?
6.3 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
6.3.1 Data Expected in July 2016
6.3.2 Other Visual Cycle Modulators
6.4 High Hopes for Complement Inhibition in Dry AMD
6.4.1 Lampalizumab (Roche): The Big News of ARVO 2013
6.4.2 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
6.5 Corticosteroids: Targeting Inflammation's Role in Dry AMD Pathogenesis
6.5.1 Iluvien (Alimera Sciences): Study terminated
6.5.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
6.6 Neuroprotection: One of Modern Medicine's Holy Grails
6.6.1 Tandospirone (Alcon): Not effective in GA
6.6.2 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
6.6.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
6.6.4 VAR10200 (Varinel): A Preclinical Candidate to Watch
6.7 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
6.7.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
6.7.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
6.7.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
6.7.4 OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
6.7.5 First iPSC Trial in Japan in Dry AMD Patients
6.7.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
6.8 Other Treatments for Dry AMD

7. Pipeline for Diabetic Retinopathy Segment, 2015-2026
7.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
7.2 Lucentis: The Game Changer for DR?
7.3 New Anti-VEGF Additions
7.3.1 Is Eylea Better than Lucentis and Avastin for DME?
7.4 Steroids in Development for DR
7.4.1 Iluvien (Alimera/pSivida): New Option in European Markets
7.4.2 A New Hope? Optina (Ampio Pharmaceuticals)
7.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
7.4.4 Cortiject (Santen): Prodrug Candidate
7.4.5 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
7.5 Other Products in Development for DR
7.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
7.5.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
7.5.3 TriLipix (Abbott): No New Development for Promising Drug
7.5.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
7.5.5 Jetrea (ThromboGenics/Novartis): Possibilities in DME?

8. Regional Market Breakdown, 2015-2026
8.1 Which Markets Hold the Most Revenue Growth Potential?
8.2 The US: Leading Market for Retinal Diseases
8.3 Japan: Strong Market Potential
8.4 EU5: Ageing Populations to Drive Market Growth
8.5 BRIC Nations: The Biggest Growth Driver for the Market

9. Qualitative Industry and Market Analysis, 2016-2026
9.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
9.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
9.3 Opportunities: New Markets and RandD Synergies
9.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
9.5 Social: Low Diagnosis, Low Compliance
9.6 Technological: Innovation for the Eye
9.7 Economic: Off-Label Treatment and Reimbursement Issues
9.8 Political: The Demography and Diabetes Challenges

10. Research Interviews
10.1 Interview with Dr. Leigh J. Hsu, Vice President, Corporate Development and Strategy, Lpath, Inc.
10.1.1 Major Changes in AMD and Other Retinal Diseases Market
10.1.2 The Landscape of Emerging Markets
10.1.3 Opportunities and Plans of Marken's Network
10.1.4 DR Market Opportunities
10.2 Interview with Philip G. Ralston, Jr., MacuCLEAR
10.2.1 MC-1101: Progress in Clinical Trials
10.2.2 MC-1101 More Effective in Early to Mid-Range AMD
10.2.3 Partnerships and Expected Launch of MC-1101

11. Report Conclusions
11.1 The Age of Lucentis: Nearing Its Conclusion?
11.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
11.3 Indications Outside Wet AMD to Gain in Importance
11.4 Dry AMD Market Has Huge Potential
11.5 Fovista Most Prominent Among the Pipeline Candidates
11.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics

Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form

List of Tables
Table 1.1 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 1.2 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 2.2 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 2.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2015
Table 3.1 Market Breakdown by Disease Segment: Revenue ($bn), Market Share (%), 2015
Table 3.2 Types of CNV in Wet AMD, Description: Approximate Proportion of Cases (%), 2014
Table 3.3 Wet AMD Segment: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.4 Wet AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2026
Table 3.5 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.6 Dry AMD Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2026
Table 3.7 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2015-2020
Table 3.8 DR Segment Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2020-2026
Table 3.9 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 3.10 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 3.11 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), Market Share (%) for 2015, 2020 and 2026
Table 4.1 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.2 Retinal Diseases Market Forecasts by Segment: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 4.3 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2020
Table 4.4 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2026
Table 4.5 Lucentis: Revenue ($bn), AGR (%), 2012-2015
Table 4.6 Lucentis, Eylea and Avastin: Comparison of Reported Characteristics
Table 4.7 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.8 Lucentis: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 4.9 Lucentis: Revenue ($bn), AGR (%), 2013-2014
Table 4.10 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.11 Eylea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 4.12 Avastin: Revenue ($bn), AGR (%), 2012-2014
Table 4.13 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.14 Avastin Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 4.15 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.16 Visudyne Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 4.17 Jetrea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 4.18 Jetrea Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 5.1 Selected RandD Pipeline for wAMD, 2015
Table 6.1 Selected RandD Pipeline for Dry AMD, 2015
Table 7.1 Selected RandD Pipeline for DR, 2015
Table 8.1 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 8.2 Regional Breakdown: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 8.3 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 8.4 US Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 8.5 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 8.6 Japan Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 8.7 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 8.8 EU5 Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 8.9 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2015-2020
Table 8.10 BRIC Nations Forecast: Revenue ($bn), AGR (%), CAGR (%), 2020-2026
Table 9.1 Strengths and Weaknesses in the AMD and Other Retinal Diseases Market, 2015
Table 9.2 Opportunities and Threats in the AMD and Other Retinal Diseases Market, 2015
Table 9.3 Social, Technological, Economic and Political Factors Influencing the AMD and Other Retinal Diseases Pharmaceutical Market (STEP Analysis), 2016-2026

List of Figures
Figure 2.1 Overall World AMD and Other Retinal Diseases Pharmaceutical Market Forecast: Revenue ($bn), 2015-2026
Figure 2.2 Market Breakdown by Product Revenue ($bn), Market Share (%), 2015
Figure 2.3 Market Breakdown by Company: Market Share (%), 2015
Figure 2.4 Leading Causes of Blindness Worldwide, Proportion of Total (%), 2010
Figure 2.5 Leading Causes of Visual Impairment (Inclusive of Blindness) Worldwide, Proportion of Total (%), 2010
Figure 3.1 Market Breakdown by Disease Segment: Revenues ($bn), 2015
Figure 3.2 Market Breakdown by Disease Segment: Market Share (%), 2015
Figure 3.3 Wet AMD Segment Forecast: Revenue ($bn), 2015-2026
Figure 3.4 Dry AMD Segment Forecast: Revenue ($bn), 2015-2026
Figure 3.5 DR Segment Forecast: Revenue ($bn), 2015-2026
Figure 3.6 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2015-2026
Figure 3.7 Retinal Diseases Market Breakdown by Segment: Revenue ($bn), 2015, 2020 and 2026
Figure 3.8 Market Breakdown by Disease Segment: Market Share (%), 2020
Figure 3.9 Market Breakdown by Disease Segment: Market Share (%), 2026
Figure 4.1 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2020
Figure 4.2 Market Breakdown by Product: Revenue ($bn), Market Share (%), 2026
Figure 4.3 Market Forecast by Product: Revenue ($bn), 2015-2026
Figure 4.4 Market Breakdown by Product: Revenue ($bn), 2015, 2020 and 2026
Figure 4.5 Lucentis: Revenues Forecast ($bn), 2015-2026
Figure 4.7 Eylea Forecast: Revenue ($bn), 2015-2026
Figure 4.8 Drivers and Restraints for Eylea, 2015
Figure 4.9 Avastin Forecast: Revenue ($bn), 2015-2026
Figure 4.10 Drivers and Restraints for Avastin, 2015
Figure 4.11 Visudyne Forecast: Revenues ($bn), 2015-2026
Figure 4.12 Jetrea Forecast: Revenues ($bn), 2015-2026
Figure 8.1 Regional Breakdown: Revenue ($bn), 2015-2026
Figure 8.2 Regional Breakdown: Revenue ($bn), 2015, 2020 and 2026
Figure 8.3 Regional Market Share (%), 2015
Figure 8.4 Regional Market Share (%), 2020
Figure 8.5 Regional Market Share (%), 2026
Figure 8.6 US Market: Revenue ($bn), 2015-2026
Figure 8.7 Japan: Revenue ($bn), 2015-2026
Figure 8.8 EU5: Grouped Revenue ($bn), 2015-2026
Figure 8.9 EU5 Breakdown Forecasts: Revenue ($bn), 2015-2026
Figure 8.10 EU5 Breakdown: Market Share (%), 2015
Figure 8.11 EU5 Breakdown: Market Share (%), 2020
Figure 8.12 EU5 Breakdown: Market Share (%), 2026
Figure 8.13 BRIC Nations Forecast: Revenue ($bn), 2015-2026
Figure 8.14 BRIC Nations Forecasts: Revenue ($bn), 2015-2026
Figure 8.15 Market Share (%) within BRIC Group by Country, 2015
Figure 8.16 Market Share (%) within BRIC Group by Country, 2020
Figure 8.17 Market Share (%) within BRIC Group by Country, 2026

Companies Listed
Abbott
Acucela
Alcon
Aldexa
Alimera Sciences
Alkeus Pharmaceuticals
Allegro
Allergan
Allergan and Molecular Partners
Ampio Pharmaceuticals
Association for Research in Vision and Ophthalmology
Avalanche Biotechnologies
Bayer Healthcare
Biotime
Biovail Corporation
Bristol-Myers Squibb
Casey Eye Institute
Chengdu Kanghong Biotech
Colby Pharmaceutical
Columbia University
CoMentis
Eli Lilly
EyeGate Pharmaceuticals
Eyetech
FDA
ForSight Vision4
Genentech
Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
GlaxoSmithKline (GSK)
iCo Therapeutics
Icon Bioscience
International Diabetes Federation
Italian Competition Authority (ICA)
Japanese Ministry of Health, Labour and Welfare
Lpath, Inc.
MacuCLEAR
Mesoblast
MSD
Neuron Systems Inc.
Neurotech
NHS
NICE
Novartis
Novo Nordisk
Ocata Therapeutics
OHR Pharmaceutical
Ophthotec Corporation
Ora Bio
Oregon Health and Science University
Othera Pharmaceuticals
Oxford BioMedica
Oxigene
PanOptica
Pfizer
QLT
Regeneron
ReVision Therapeutics
Roche
Santen Pharmaceutical
Sirion Therapeutics
StemCells
Stemedica Cell Technologies
ThromboGenics
Tyrogenex
UCB
UK's General Medical Council
University College London (UCL)
US National Eye Institute
Valeant Pharmaceuticals
Varinel
VisionCare Ophthalmic Technologies
Vitreoretinal Technologies
WHO
Xcovery Group
Xcovery Vision

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Virology and Bacteriology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales and Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

2016 Infectious Disease Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Microbiology Tests, Technology Trends, Opportunities for Suppliers

  • $ 54501
  • Industry report
  • October 2016
  • by Venture Planning Group

This unique 33-country survey from VPGMarketResearch.com contains over 2,100 pages, 875 tables and provides data and analysis not available from any other published source. The survey is designed to assist ...

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

2016 Microbiology Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from any other published source. The survey is designed ...


Download Unlimited Documents from Trusted Public Sources

Eye Disease Statistics in the UK

  • December 2016
    9 pages
  • Eye Disease  

    Ophthalmology  

  • United Kingdom  

View report >

Therapy Market and Diabetes Statistics in the UK

  • November 2016
    9 pages
  • Therapy  

    Statins  

    Diabetes  

  • United Kingdom  

View report >

Therapy and Cardiovascular Drug Market in Europe

  • November 2016
    6 pages
  • Therapy  

    Cardiovascular ...  

    ACE Inhibitor  

  • Europe  

View report >

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.